AI-Driven Drug Repurposing: Developing Therapeutics Through Data and Discovery

Abstract This paper explores the transformative role of artificial intelligence (AI) in drug repurposing, a strategy for identifying new therapeutic uses for existing drugs. By leveraging pre-existing knowledge of drugs, AI enables rapid evaluation of drug efficacy, significantly shortening the drug development timeline compared to traditional methods. AI approaches, including machine learning and deep learning, enhance the identification of suitable biological targets, predict drug-disease associations, and facilitate the analysis of complex biological data and literature. Case studies demonstrate the effectiveness of AI in rapidly repurposing drugs, such as remdesivir during the COVID-19 pandemic. However, challenges remain, including data bias, model interpretability, and ethical considerations. The future of AI-driven drug repurposing holds promise for personalized medicine and collaborative innovations, potentially revolutionizing global healthcare outcomes.

Institutions

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2025-05-25
DOI
https://doi.org/10.5281/zenodo.15569468
Primary Topic
Computational Drug Discovery Methods
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

AI-Driven Drug Repurposing: Developing Therapeutics Through Data and Discovery

Zenodo (CERN European Organization for Nuclear Research)
Computational Drug Discovery Methods
article

AI-Driven Drug Repurposing: Developing Therapeutics Through Data and Discovery

article en

Abstract

Abstract This paper explores the transformative role of artificial intelligence (AI) in drug repurposing, a strategy for identifying new therapeutic uses for existing drugs. By leveraging pre-existing knowledge of drugs, AI enables rapid evaluation of drug efficacy, significantly shortening the drug development timeline compared to traditional methods. AI approaches, including machine learning and deep learning, enhance the identification of suitable biological targets, predict drug-disease associations, and facilitate the analysis of complex biological data and literature. Case studies demonstrate the effectiveness of AI in rapidly repurposing drugs, such as remdesivir during the COVID-19 pandemic. However, challenges remain, including data bias, model interpretability, and ethical considerations. The future of AI-driven drug repurposing holds promise for personalized medicine and collaborative innovations, potentially revolutionizing global healthcare outcomes.

Zenodo (CERN European Organization for Nuclear Research)
Saveetha University (IN)
Openalex Percentile: Top 51%
Computational Drug Discovery Methods
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

AI-Driven Drug Repurposing: Developing Therapeutics Through Data and Discovery · Zenodo (CERN European Organization for Nuclear Research) (2025) | TGRS Research Map | TGRS